Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 12Brain Neoplasms 6Breast Neoplasms, Male 5Glioblastoma 4Gliosarcoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Oligodendroglioma 2Glioma 2Gallbladder Neoplasms 2Ependymoma 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Astrocytoma 2Tongue Neoplasms 1Thyroid Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Neoplasms 1Melanoma 1Medulloblastoma 1Insulin-Like Growth Factor I, Resistance To 1Familial ependymoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 4Bevacizumab 3Vorinostat 2Immunoglobulin G 2Disulfides 2veliparib 1romidepsin 1ispinesib 1cediranib 1Vincristine 1Prednisone 1Nivolumab 1Methotrexate 1Lomustine 1Lapatinib 1Irinotecan 1Ifosfamide 1Gelclair 1Fluorodeoxyglucose F18 1Etoposide 1Dexamethasone 1Clinical Laboratory Techniques 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1CK0238273 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Spinal Cord Neoplasms × Lapatinib × Clear all
NCT00826241 2019-03-22

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
58 enrolled 11 charts
CNS

Brain Neoplasms, Ependymoma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡